



New insights in COVID-19-associated chilblains: A comparative study with chilblain lupus erythematosus

Gilles Battesti, Jihane El Khalifa, Nour Abdelhedi, Valentine Ferre, Fabrice Bouscarat, Catherine Picard-Dahan, Florence Brunet-Possenti, Gilles Collin, Justine Lavaud, Patrick Le Bozec, et al.

► To cite this version:

Gilles Battesti, Jihane El Khalifa, Nour Abdelhedi, Valentine Ferre, Fabrice Bouscarat, et al.. New insights in COVID-19-associated chilblains: A comparative study with chilblain lupus erythematosus. *Journal of The American Academy of Dermatology*, 2020, 83 (4), pp.1219-1222. 10.1016/j.jaad.2020.06.1018 . hal-03295375

HAL Id: hal-03295375

<https://cnrs.hal.science/hal-03295375>

Submitted on 9 Sep 2022

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

New insights in COVID-19-associated chilblains: a comparative study with chilblain lupus erythematosus

Gilles Battesti, MD¹; Jihane El Khalifa, MD²; Nour Abdelhedi, MD²; Valentine Ferre, PharmD³; Fabrice Bouscarat, MD²; Catherine Picard-Dahan, MD²; Florence Brunet-Possenti, MD²; Gilles Collin³, Justine Lavaud, MD²; Patrick Le Bozec, MD²; Marion Rousselot, MD²; Amélie Tournier, MD²; Coralie Lheure, MD²; Anne Couvelard, MD, PhD¹; Salima Hacein-Bey-Abina, PharmD, PhD^{4,5}; Amine.M Abina, MD, PhD^{4,6}; Charlotte Charpentier, PharmD, PhD³; Sabine Mignot, PharmD, PhD⁷; Pascale Nicaise, PharmD, PhD⁷; Diane Descamps, MD, PhD³; Lydia Deschamps, MD¹; Vincent Descamps, MD, PhD²

1. Department of Pathology, Bichat Hospital, 46 rue Henri Huchard 75877 Paris, France.
2. Department of Dermatology, Bichat Hospital, 46 rue Henri Huchard 75877 Paris, France.
3. Department of Virology, Bichat Hospital, 46 rue Henri Huchard 75877 Paris, France.
4. UTCBS CNRS UMR 8258, INSERM U1267, Faculté de Pharmacie de Paris, Université de Paris, 4 av. de l'observatoire, 75006 Paris, France
5. Clinical Immunology Laboratory, Groupe Hospitalier Universitaire Paris-Sud, Hôpital Kremlin-Bicêtre, Assistance Publique-Hôpitaux de Paris, 78, r. du Général-Leclerc, 94270 Le-Kremlin-Bicêtre, France.
6. Cerba Healthcare, Cerballiance-Ile-de-France Ouest, Hôpital Privé de l'Ouest Parisien, 14 Rue Castiglione del Lago, 78190 Trappes
7. Department of Immunology, Bichat Hospital, 46 rue Henri Huchard 75877 Paris, France.

Corresponding author and reprint requests:
 Vincent Descamps, MD, PhD, Department of Dermatology, Bichat Hospital, 46 rue Henri Huchard 75877 Paris, France.
 Telephone: 01 40 25 73 00
 Fax: 01 40 25 73 03
 E-mail: vincent.descamps@aphp.fr

Funding sources: None
 Conflicts of Interest: None
 IRB approval status: Approved by the institutional review board of HUPNVS, Paris 7 University, AP-HP (IRB 00006477)
 Statement of any prior presentation: none

Manuscript word count: 499 words
 References: 5
 Figures: 0
 Supplementary figures: 0
 Tables: 2
 Supplementary tables: 0

46 **Abbreviation and acronym list:**

47 Epidemic chilblain: EC

48 Chilblain lupus erythematosus: CLE

49 Type-1 interferon: IFN-1

50 Plasmacytoid dendritic cells: pDCs

51 Antineutrophils cytoplasmic antibodies: ANCA

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

To the Editor: An unexpected outbreak of chilblain has been reported in association with Coronavirus disease 19 (COVID-19)¹. SARS-CoV-2 infection has been demonstrated in a few documented cases of chilblain. Chilblain may also be observed in acquired lupus and rarely as a manifestation of a familial disorder related to interferonopathies. To enhance understanding of this «epidemic chilblain» (EC) and their relevance to SARS-CoV-2 infection, we studied clinical, haemato-immunological, histopathological, immunohistochemical and virological characteristics of 7 EC cases and compared them with 11 previous cases of chilblain lupus erythematosus (CLE).

EC patients were included between February and April 2020 and were suspected of COVID-19 because they presented with COVID-19 symptoms or were in close contact with presumed/confirmed COVID-19 patients. Exclusion criteria were patients with previous chilblain episode, cold exposure preceding chilblain occurrence and history of known auto-immune disorder. For each patient, we collected demographic data, clinical and laboratory tests, including exhaustive haemato-immunological screening, cutaneous histology (including immunostaining for CD123, a plasmacytoid dendritic cells (pDCs) marker, and MxA, a type-I interferon (IFN-I)-induced protein) and virological studies.

The clinico-biological findings of EC and CLE cases are summarized in Table 1. Hands, ears, or nose localisation were more frequently observed in CLE group (82% vs 0%). Anti-nuclear antibodies were only detected in the CLE group (91% vs 0%). Age of onset of chilblain, sex, pre-existing Raynaud's phenomenon and other immunological abnormalities did not differ between groups. Antineutrophil cytoplasmic antibodies (ANCA) and lupus-type circulating anticoagulant were found in two and one EC patients, without any clinical manifestation of ANCA vasculitis or thrombosis. No EC patient had cryoprotein, cold agglutinin or anticardiolipin antibodies.

Our 7 EC cases were histologically similar to CLE. High expression of CD123 and MxA were observed in both groups (table 2).

SARS-CoV-2 RNA detection performed at a median delay of 23 days after symptoms onset (10-36) was negative in nasopharyngeal, skin biopsies and plasma samples. Repeated SARS-CoV-2 IgG/IgA

tests were negative for all patients except for one case who showed an isolated IgA positivity (time between first symptoms and serologies ranged 21-51 days).

Active Human herpes virus type 6, 7, 8 and Epstein Barr virus infections were excluded by reliable tests (PCR).

These results confirmed that chilblains may be considered as a manifestation of high production of IFN-I as observed in interferonopathies. These patients may exhibit only IFN-I associated symptoms or minor forms of COVID-19 infection. High level of IFN-I was associated with moderate cases of COVID-19². Interferon-induced proteins such as IFITM (interferon-induced trans-membrane) 1, 2 and 3 inhibit early replication of several enveloped RNA viruses, such as MERS-coronaviruses³. In addition, active viral replication may not be necessary to mount an efficient IFN response in SARS-CoV infection⁴. IFN-I may also suppress antibody responses that might explains the negativity of the serologies in most patients with EC⁵.

SARS-Cov-2 infection may induce in some predisposed patients a high production of IFN-I responsible for a high innate immune protective response. This hypothesis provides additional arguments to propose early IFN treatment for infected high-risk patients.

References:

1. de Masson A, Bouaziz J-D, Sulimovic L, et al. Chilblains are a common cutaneous finding during the COVID-19 pandemic: a retrospective nationwide study from France. *J Am Acad Dermatol*. Published online May 4, 2020. doi:10.1016/j.jaad.2020.04.161
2. Impaired type I interferon activity and exacerbated inflammatory responses in severe Covid-19 patients | medRxiv. Accessed May 14, 2020. <https://www.medrxiv.org/content/10.1101/2020.04.19.20068015v1>
3. Wrensch F, Winkler M, Pöhlmann S. IFITM Proteins Inhibit Entry Driven by the MERS-Coronavirus Spike Protein: Evidence for Cholesterol-Independent Mechanisms. *Viruses*. 2014;6(9):3683-3698. doi:10.3390/v6093683
4. de Lang A, Baas T, Smits SL, Katze MG, Osterhaus AD, Haagmans BL. Unraveling the complexities of the interferon response during SARS-CoV infection. *Future Virol*. 2009;4(1):71-78. doi:10.2217/17460794.4.1.71
5. Fallet B, Narr K, Ertuna YI, et al. Interferon-driven deletion of antiviral B cells at the onset of chronic infection. *Sci Immunol*. 2016;1(4). doi:10.1126/sciimmunol.aah6817

Table 1. Clinical and biological findings in EC and CLE

Variable	EC n = 7	CLE n = 11	P Value
Female, n (%)	4 (57)	7 (64)	1
Mean age (SD)	42 (10)	49 (15)	0.27
Previous Raynaud’s phenomenon, No (%)	4 (57)	4 (36)	0.63
Previous other cutaneous symptoms, No (%)	3 ^a (43)	8 (73)	0.33
Feet-localized localisation, No (%)	7 (100)	2 (18)	<0.01
COVID-19 symptoms, No (%)	5 (71)	NA	-
Potential SARS-CoV-2 contact, No (%)	4 (57)	NA	-
Positive anti-nuclear antibodies, No (%)	0 (0)	10 (91)	<0.01
Presence of other immunological abnormalities, No (%)	3 ^b (43)	9 (82)	0.14

Abbreviations : SD= standard deviation ; NA= not applicable.
^aTwo patients had acrocyanosis and one patient had photosensitivity.
^bTwo patients had ANCA and one patient had lupus-type circulating anticoagulant.

Table 2. Histological and Immunohistochemical comparison between EC and CLE

Variable		EC n = 7	CLE n = 11	P Value
Epidermis				
Lymphocyte exocytosis, No (%)		3 (43)	7 (64)	0.63
Confluent necrosis, No (%)		1 (14)	0 (0)	0.39
Apoptotic keratinocytes, No (%)		2 (29)	4 (36)	1
Vacuolized basement membrane zone, No (%)		1 (14)	8 (73)	0.049
Papillary dermis				
Oedema, No (%)		4 (57)	2 (18)	0.14
Lymphocyte infiltrate intensity score ^a , median (ranges)		2 (1 – 3)	2 (1 - 3)	0.34
Lymphocyte infiltrate localization, No (%)				
	Perivascular localisation	7 (100)	11 (100)	1
	Interstitial localisation	3 (43)	8 (73)	0.33
Other inflammatory cell infiltrate, No (%)		2 (29)	3 (27)	1
Lymphocytic vasculitis, No (%)		5 (71)	1 (9)	0.01
Congestive vessels, No (%)		2 (29)	0 (0)	0.13
Red blood cell extravasation, No (%)		4 (57)	1 (9)	0.047
Reticular and deep dermis				
Lymphocyte infiltrate intensity score ^a , median (range)		2 (1 - 3)	2 (0 - 3)	0.77
Lymphocyte infiltrate localization, No (%)				
	Perivascular	7 (100)	10 (91)	1
	Interstitial	0 (0)	0 (0)	1
	Peri-eccrine	6 (86)	7/10 (70) ^b	0.60
	Peri-neural	4 (57)	7/9 (78) ^c	0.59
Other inflammatory cell infiltrate, No (%)		2 (29)	3 (27)	1
Lymphocytic vasculitis, No (%)		4 (57)	7 (64)	1
Leucocytoclastic vasculitis, No (%)		1 (14)	1 (9)	1
Congestive vessels, No (%)		3 (43)	1 (9)	0.24

Median of neural section (range)	5 (2 – 9)	3 (0 – 4)	0.008
Hypodermis^d			
Perivascular lymphocyte infiltrate, No (%)	2/2 (100)	0/2 (0)	0.33
Immunohistochemical features			
Case with MxA+ cells, No (%)	7 (100)	10/10 (100) ^e	1
MxA expression, median value (range)	180 (105 – 280)	270 (120 – 300)	0.28
Case with CD123+ cells, No (%)	6 (86)	9/10 (90) ^e	1
CD123 expression, median value (range)	50 (0 – 60)	15 (0 – 100)	0.32
Positive cutaneous DIF, No (%)	0/3 (0) ^f	1/2 (50) ^g	0.4

Abbreviations: SD = standard deviation; MxA = myxovirus resistance protein A; DIF = Direct

Immunofluorescence

^a Intensity was scored as follow: 0= absence, 1= rare, 2= moderated, 3= intense;

^b One of CLE biopsy did not show eccrine gland;

^c Two of CLE did not show nerve;

^d Hypodermis was observed in 2 biopsies in each groups;

^e One LCE could not have immunohistochemistry analyse;

^f 3 DIF were performed in the epidemic chilblain group;

^g 2 DIF were performed in the lupus chilblain group; SD = standard deviation.

176 An unexpected outbreak of chilblain has been observed with Coronavirus disease 19 (COVID-19)^{1,6}.
 177 SARS-CoV-2 infection has been demonstrated in a few documented cases of chilblain⁷⁻⁹.
 178 Chilblain may also be observed in acquired lupus and rarely as a manifestation of a familial disorder
 179 related to interferonopathies¹⁰.
 180 To enhance understanding of these « epidemic chilblains » (EC) and their relevance to SARS-CoV-2
 181 infection, we studied clinical, haemato-immunological, histopathological, immunohistochemical and
 182 virological characteristics of seven EC cases and compared them with lupus chilblain erythematosus
 183 (CLE).
 184
 185 EC patients were included between February and April 2020 and were suspected of COVID-19
 186 because they presented with COVID-19 symptoms or were in close contact with
 187 presumed/confirmed COVID-19 patients. Exclusion criteria were patients with previous chilblain
 188 episode, cold exposure preceding chilblain occurrence and history of known auto-immune disorder.
 189 For each patient, we collected data about sex, age, clinical and laboratory tests, including haemato-
 190 immunological screening, cutaneous histology (immunostains for CD123 a plasmacytoid dendritic
 191 cells (pDCs) marker and MxA, a type-I interferon (IFN-I)-induced protein) and **virological studies**.
 192 The clinico-biological findings of EC and CLE cases are summarized in Table 1.
 193
 194
 195 Hands, ears, or nose localisation were more frequently observed in CLE group (82% vs 0%). ANA were
 196 detected only in the CLE group (91% vs 0%). Antineutrophils cytoplasmic antibodies (ANCA) and
 197 lupus-type circulating anticoagulant were found in two and one patient, without any manifestation
 198 of ANCA vasculitis or thrombosis. No patient had, cryoprotein, cold agglutinin or anticardiolipin
 199 antibodies.
 200 Age of onset of chilblain, sex, pre-existing Raynaud's phenomenon and other immunological
 201 abnormalities did not differ between groups.

Our 7 EC cases were histologically similar to CLE. High expression of CD123 and MxA were observed in both groups (table 2).

These results confirmed that chilblains may be considered as a manifestation of high production of IFN-I as observed in interferonopathies. These patients may exhibit only IFN-I associated symptoms or minor forms of COVID-19 infection. High level of IFN-I was associated with moderate cases of COVID-19². Interferon-induced proteins such as IFITM (interferon-induced trans-membrane) 1, 2 and 3 also inhibits early replication of several enveloped RNA viruses, such as MERS-coronaviruses¹¹. In addition, active viral replication may not be necessary to mount an efficient IFN response in SARS-CoV infection⁴. IFN-I may also suppress antibody that explain the negativity of the serologies in most patients with EC.

SARS-Cov-2 infection may induce in some predisposed patients a high production of IFN-I responsible for a high innate immune protective response.

This hypothesis provides additional arguments to propose early IFN treatment for infected high-risk patients.

REFERENCES :

1. de Masson A, Bouaziz J-D, Sulimovic L, et al. Chilblains are a common cutaneous finding during the COVID-19 pandemic: a retrospective nationwide study from France. *J Am Acad Dermatol*. Published online May 4, 2020. doi:10.1016/j.jaad.2020.04.161
2. Impaired type I interferon activity and exacerbated inflammatory responses in severe Covid-19 patients | medRxiv. Accessed May 14, 2020. <https://www.medrxiv.org/content/10.1101/2020.04.19.20068015v1>
3. Wrensch F, Winkler M, Pöhlmann S. IFITM Proteins Inhibit Entry Driven by the MERS-Coronavirus Spike Protein: Evidence for Cholesterol-Independent Mechanisms. *Viruses*. 2014;6(9):3683-3698. doi:10.3390/v6093683
4. de Lang A, Baas T, Smits SL, Katze MG, Osterhaus AD, Haagmans BL. Unraveling the complexities of the interferon response during SARS-CoV infection. *Future Virol*. 2009;4(1):71-78. doi:10.2217/17460794.4.1.71
5. Fallet B, Narr K, Ertuna YI, et al. Interferon-driven deletion of antiviral B cells at the onset of chronic infection. *Sci Immunol*. 2016;1(4). doi:10.1126/sciimmunol.aah6817
6. Galván Casas C, Català A, Carretero Hernández G, et al. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. *Br J Dermatol*. Published online April 29, 2020. doi:10.1111/bjd.19163
7. Kolivras A, Dehavay F, Delplace D, et al. Coronavirus (COVID-19) infection-induced chilblains: A case report with histopathologic findings. *JAAD Case Rep*. Published online April 18, 2020. doi:10.1016/j.jdc.2020.04.011
8. Locatelli AG, Robustelli Test E, Vezzoli P, et al. Histologic features of long lasting chilblain-like lesions in a pediatric COVID-19 patient. *J Eur Acad Dermatol Venereol JEADV*. Published online May 9, 2020. doi:10.1111/jdv.16617
9. Alramthan A, Aldaraji W. A case of COVID-19 presenting in clinical picture resembling chilblains disease. First report from the Middle East. *Clin Exp Dermatol*. Published online April 17, 2020. doi:10.1111/ced.14243
10. Zimmermann N, Wolf C, Schwenke R, et al. Assessment of Clinical Response to Janus Kinase Inhibition in Patients With Familial Chilblain Lupus and TREX1 Mutation. *JAMA Dermatol*. 2019;155(3):342-346. doi:10.1001/jamadermatol.2018.5077
11. Zhao X, Sehgal M, Hou Z, et al. Identification of Residues Controlling Restriction versus Enhancing Activities of IFITM Proteins on Entry of Human Coronaviruses. Williams BRG, ed. *J Virol*. 2017;92(6):e01535-17, /jvi/92/6/e01535-17.atom. doi:10.1128/JVI.01535-17